Kevin Conlon

3PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Oct 31, 2023
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.

Rom Leidner, Kevin Conlon, Douglas G McNeel

|Nov 20, 2021
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.

Kevin Conlon, Dionysios C Watson, Thomas A Waldmann

|Apr 22, 2021
Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.

Sigrid P Dubois, Milos D Miljkovic, Thomas A Fleisher

Pageof 1

Frequent Collaborators

2 joint publications

Thomas A Waldmann

2 joint publications

George N Pavlakis

2 joint publications

Rom Leidner

2 joint publications

Douglas G McNeel